In the main text, we show the effect of antiviral treatment on viral titer. In this supplement, we include the graphs showing the effect of viral titer treatment on the eclipse and infectious cells (Figs. 1 & 2) . There are experimental techniques that allow measurement of infected cells (1-3), but they do not discriminate between cells in the eclipse phase and those in the infectious phase. We see, however, that even if we measure the time course of infected cells, the decay rate alone will not provide sufficient information to extract the efficacy of the antiviral. The slope of the decay phase changes not only with drug efficacy, but also changes as base infection parameters change.
For simulations of this model, we use parameters determined by fits of this model to patient data (Table 1 ) (4). We plot the viral titers for treatment applied with different time delays and with different efficacies in Fig. 3 . As in the main text, the figure also shows the viral titers when base parameters are varied ten-fold. Fig. 4 shows the decay rates calculated as a function of the treatment delay. We find that the results for the TIV model are similar to the results found in the main text with some dependence of decay rate on drug efficacy as long as treatment is applied before the viral peak, but no dependence on drug efficacy if treatment is applied after the peak. Since we often do not know whether we are applying the drug before or after the peak, we cannot determine drug efficacy from this measurement. Oseltamivir treatment is applied at various times post infection and at different efficacies. Top graph shows the effect of different treatments on the base viral infection parameters. The effect of varying the base infection parameters is also explored by either decreasing (bottom row) or increasing (upper row) viral production rate (p) (first column), infection rate (β) (second column), viral clearance rate (c) (third column), infectious lifespan (τ I ) (last column) by 10-fold compared to the base parameters. Figure 4: Effect of treatment delay on viral titer decay for a TIV model. Oseltamivir treatment is applied at various times post infection and at different efficacies. The effect of varying the base infection parameters is also explored by either decreasing (bottom row) or increasing (top row) viral production rate (p) (first column), infection rate (β) (second column), viral clearance rate (c) (third column), eclipse duration (τ E ) (fourth column), infectious lifespan (τ I ) (last column) by 10-fold (except τ E , see text) compared to the base parameters.
